PRE

8.80014.65%
PA

Pasi Antero Janne

Member of Scientific & Medical Advisory Board

Dr. Pasi Antero Janne, Ph.D., M.D. is Senior Vice President of Translational Medicine of Dana-Farber Cancer Institute, Inc. Dr. Janne has M.D. from University of Pennsylvania. He is Member of Scientific Advisory Board of TOLREMO therapeutics AG from March 2025. He is Member of Scientific Advisory Board at Treadwell Therapeutics Inc. since February 2024. He serves as Member of Scientific Advisory Board at Duality Biotherapeutics, Inc. He serves as Member of Clinical Advisory Board at Phanes Therapeutics, Inc. since September 05, 2023. He serves as Member of Scientific & Medical Advisory Board of Prenetics Global Limited since March 2023. He serves as Member of Scientific Advisory Board at Allorion Therapeutics Inc. He is a globally renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. His translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC. Prof. Jänne has received multiple awards for his work including from the AACR, ESMO and ASCO. He is a Member of Scientific Advisory Board at Frontier Medicines Corporation from July, 2022. He serves as Member of Clinical Scientific Advisory Board at Scorpion Therapeutics, Inc. since November 2022. He served as a Member of Scientific Advisory Board at Transcenta Holding Ltd. He serves as Member of the Scientific Advisor at Voronoi, Inc. He had been a Member of Scientific Advisory Board of Silicon Therapeutics LLC since December 2020 until June 2022. He has been Scientific Advisory Board at Mirati Therapeutics, Inc. since January 2019. He serves as Scientific Advisor of Biocartis NV. He serves as Scientific co-Director of the Belfer Center for Applied Cancer Sciences. He serves as Member of Scientific & Medical Advisory Board at Genprex, Inc. He serves as Member of Scientific Advisory Board at Loxo Oncology, Inc. He serves as a Member of Scientific Advisor Board at Ignyta, Inc. He served as a Member of Scientific Advisory Board of Transgenomic Inc. since January 17, 2008. He serves as Associate Professor of Medicine, Harvard Medical School and clinician at Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology. He is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is a leading researcher in medical oncology and lung cancer and is Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer Center. His research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents, as well as mechanisms of sensitivity and resistance targeted cancer therapies. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. He has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, the Bonnie J. Addario Lung Cancer Foundation, the American Association of Cancer Research and the European Society of Medical Oncology. He served as Member of Scientific Advisory Board at Nuvalent, Inc. He is the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a Member of the 2010 AACR Team Science Award, American Cancer Research Clinical Research Professorship (2017), Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research from the American Association for Cancer Research (2018), Translational Research Award from the European Society for Medical Oncology (2018), R35 - Outstanding Investigator Award from the National Cancer Institute (2018) and Science of Oncology Award from the American Society of Clinical Oncology (2020). He is an elected Member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship. He received his M.D. and Ph.D. from The University of Pennsylvania in 1996 and his B.A. degree from Vassar College. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. He is clinical advisor, Dana Farber Cancer Institute.

Positions